There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Opko Health (OPK – Research Report) and Sagimet Biosciences, Inc. Class A (SGMT – Research Report) with bullish sentiments.
Opko Health (OPK)
In a report released today, Edward Tenthoff from Piper Sandler reiterated a Buy rating on Opko Health, with a price target of $5.00. The company’s shares closed last Thursday at $1.50.
According to TipRanks.com, Tenthoff is a 4-star analyst with an average return of
The word on The Street in general, suggests a Strong Buy analyst consensus rating for Opko Health with a $3.33 average price target, representing an 113.5% upside. In a report issued on September 21, Barrington also maintained a Buy rating on the stock with a $2.00 price target.
See the top stocks recommended by analysts >>
Sagimet Biosciences, Inc. Class A (SGMT)
Piper Sandler analyst Yasmeen Rahimi maintained a Buy rating on Sagimet Biosciences, Inc. Class A today and set a price target of $67.00. The company’s shares closed last Thursday at $9.06.
According to TipRanks.com, Rahimi is a 3-star analyst with an average return of
Currently, the analyst consensus on Sagimet Biosciences, Inc. Class A is a Strong Buy with an average price target of $43.33, implying a 361.4% upside from current levels. In a report issued on September 26, JMP Securities also reiterated a Buy rating on the stock with a $30.00 price target.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Read More on OPK:
